The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).
 
Elizabeth Stephanie Ahern
Patents, Royalties, Other Intellectual Property - QIMR
Travel, Accommodations, Expenses - Amgen; Merck Sharp & Dohme
 
Annette Cubitt
No Relationships to Disclose
 
Emma Ballard
No Relationships to Disclose
 
Michele W.L. Teng
Honoraria - Arcus Biosciences; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - Bristol-Myers Squibb; Tizona Therapeutics, Inc.
 
William C. Dougall
Honoraria - Amgen
Consulting or Advisory Role - Cascadia Drug Development Group; Omeros
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - QIMR
 
Mark J. Smyth
Stock and Other Ownership Interests - Tizona Therapeutics, Inc.
Consulting or Advisory Role - Arcus Biosciences; Bristol-Myers Squibb; Elstar Therapeutics; Merck Sharp & Dohme; Nektar; Tizona Therapeutics, Inc.
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Tizona Therapeutics, Inc.
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
Expert Testimony - Corvus Pharmaceuticals
 
Brett Gordon Maxwell Hughes
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche